Back

Supervisory Board

  1. Supervisory Board

Supervisory Board

Flemming Ornskov, MD, MPH

Non-Executive Chairman of the Supervisory Board

Flemming Ornskov, MD, MPH. With his term beginning on April 1, 2019, Dr. Ornskov has been approved as the Chairman of the Supervisory Board of CENTOGENE. In October of 2019 he was appointed Chief Executive Officer of Galderma SA, and prior to ... 

... this appointment he served as Chief Executive Officer and Non-Executive Director of Shire Plc from April 2013 to January 2019 when Shire was acquired by Takeda.

Dr. Ornskov has extensive international, strategic and operational experience in the pharmaceutical and biotech sectors, as well as medical expertise as a physician with training in pediatrics. He was Non-Executive Chairman of the Board of Recordati S.p.A. from February 2019 until April 2020. He is currently Non-Executive Chairman of the Waters Corporation Inc, and Non-Executive Director of Karo Pharma AB. Dr. Ornskov was Non-Executive Chairman of Evotec AG from 2008 to 2012 and Non-Executive Director of PCI Biotech Holding from 2008 to 2013. From 2010 to 2013, he was Chief Marketing Officer and Global Head, General and Specialty Medicine at Bayer AG. He also previously held positions as Global President, Pharmaceuticals and Over-the Counter at Bausch & Lomb; Chairman, President and Chief Executive Officer of LifeCycle Pharma A/S (now Veloxis A/S), President and Chief Executive Officer of Ikaria Inc., and various senior executive roles at Merck Inv and Novartis AG. Dr. Ornskov received his MD from the University of Copenhagen, MBA from INSEAD, and Masters of Public Health from Harvard University.

Peer Schatz

Vice Chairman of the Supervisory Board

Peer is the Managing Director of PS Capital Management GmbH, which provides capital and support to emerging companies, primarily in the Life Sciences industry.

He joined CENTOGENE from his previous position as long-time Chief Executive Officer of QIAGEN N.V. (Nasdaq: QGEN; Frankfurt: QIA), a leading provider of molecular sample and assay technologies. From 1993 to 2019, he led QIAGEN's rapid expansion from a start-up company with $2 million in sales into a global leader in molecular testing with over $1.6 billion in revenues. Prior to joining QIAGEN, Peer participated in the founding of several startup companies in the IT industry and also held positions at ComputerLand AG and Sandoz AG. Peer served as a founding member of the German Corporate Governance Commission, as a Vice Chairman of the Supervisory Board of Evotec AG, as Vice Chairman of AdvaMedDx (an in-vitro diagnostics industry organization in the United States) and as Director of the U.S. Analytical & Life Science and Diagnostic Association (ALDA). He graduated from the University of St. Gallen, Switzerland, with a master’s degree in Finance and from the University of Chicago Graduate School of Business with an MBA

Hubert Birner, PhD

Member of the Supervisory Board

Dr. Birner, Managing Partner, Montreal and Munich, is responsible for TVM Capital Life Science’s overall investment strategy and fund operations in North America and Europe. Dr. Birner joined TVM Capital in 2000 as an investment manager. He currently serves as ...

... Chairman of the board of directors of Noxxon Pharma N.V., SpePharm Holdings BV, leon nanodrugs GmbH, Argos Therapeutics and AL-S Pharma AG. He is also a member of the board of directors of Proteon Therapeutics Inc. and Acer Therapeutics Inc. Dr. Birner previously served on the board of directors of Horizon Pharma, Inc., Bioxell SA, Evotec AG, Probiodrug AG and Jerini AG. Prior to his current tenure, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development.

Before starting his professional career in business, he earned substantial academic merits, including a position as Assistant Professor for biochemistry at the Ludwig-Maximilian-University (LMU), following his summa cum laude doctoral degree in biochemistry at LMU; his doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Dr. Birner also holds an MBA from Harvard Business School.

Holger Friedrich

Member of the Supervisory Board

Holger has more than 25 years of experience in the IT industry. His focus is on software engineering and IT architecture management. Holger holds several leadership positions in leading institutions, including partner of a global management consulting firm and as an ...

... executive board member in several technology firms. He served as chairman of SPM Technologies (acquired by SAP), was Partner at McKinsey and Board member at Software AG. Besides that, Holger was executive board member of CORE, a think tank for technologies in the financial services industry.

Berndt Modig , MBA

Member of the Supervisory Board

Berndt is an independent non-executive director and a biotech entrepreneur. He has more than 25 years of experience working with biotech companies and currently serves as a director and Audit Committee chair of .....

... Axovant Sciences Ltd., he is a member of the Audit Committee of Affimed N.V. and vice chairman of the Supervisory Board and chair of the Audit Committee of Kiadis Pharma N.V., all publicly held pharmaceutical companies. In addition to that, he is also the Chief Executive Officer and co-founder of Pharvaris BV.

Previously, Berndt was Chief Financial Officer of Prosensa Holding N.V., a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases, from March 2010 through its IPO on the NASDAQ in 2013 until its acquisition by BioMarin Pharmaceutical Inc. in 2015. Prior to Prosensa, Berndt was Chief Financial Officer at Jerini AG through its IPO on the Frankfurt exchange in 2005 and sale to Shire Plc in 2008.

Berndt also formerly served as Chief Financial Officer at Surplex AG from 2001 to 2003, and from 1999 to 2001 was the Finance Director Europe of U.S.-based Hayward Industrial Products Inc. In previous positions he was a Partner in the Brussels-based private equity firm Agra Industria and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York.

Berndt received a bachelor´s degree in business administration, economics and German from the University of Lund, Sweden, and an M.B.A from INSEAD, Fontainebleau, France.

Guido Prehn

Member of the Supervisory Board

Guido has over 15 years of experience in the private equity industry. After several years in the investment banking department of Merrill Lynch, Guido gathered international investing experience at TPG Capital and Allianz Capital Partners.

In 2008 he built Deutsche Private Equity as the preeminent growth private equity platform for Mittelstand companies in the German speaking region. Ever since, he has supported numerous fast growing SMEs as an investor and board member.

Guido studied business administration at the European Business School, Oestrich-Winkel, De Paul University Chicago and Universidad Argentina de la Empresa, Buenos Aires.

Eric Souetre, MD

Member of the Supervisory Board

Eric has an extensive track record in the Lifescience and Biotech industry for the past decades. He initiated his career in medical research at the National Institute of Health (USA), being a former Assistant Professor of Paris Medical University.

He holds a PhD in Neurosciences by the Marseille University and a Medical Degree (MD) by the Medical University of Nice. He founded Benefit, a research and consulting company in 1990, that expanded rapidly to over six European countries and Canada before being acquired by Quintiles Inc. (USA) in 1995. As board member, Eric then took over worldwide responsibility in consulting for Quintiles Inc. and remained as a board member for several years.

In 2003, he co-founded Labco, and led the company to a European leadership as chairman and CEO until late 2010. Eric then remained as active board member, especially involved into the selling of Labco to Cinven in 2015.